21st Annual · March 2023 · Virtual

2023

23 faculty
4 recordings

Symposium

Friday, March 17, 2023

Full recording 1 178 min Full recording 2 127 min

10:00 am
Introductory Notes on the 21st Annual MCI Symposium
Ranjan Duara, MD, FAANMt Sinai Medical Center/Wien Center for Alzheimer's Disease and Memory Disorders

10:15

Session 1

Highlights from Observational Studies of Brain Aging (including, cognition, imaging, blood based biomarkers and longitudinal predictors of decline)

Co-Chairs: Mary Ganguli, MD, MPHUniversity of Pittsburgh; Ronald Petersen, MD, PhDMayo Clinic, Rochester

10:15
Session Overview
10:20
Fluid and Imaging Biomarker Changes in the Swedish BioFINDER 2 Study
Oskar Hansson, MD, PhDLund University
10:40
Fluid and Imaging Biomarker Changes in the Mayo Clinic Study of Aging
Alicia Algeciras-Schimnich, PhDMayo Clinic, Rochester
11:00
Fluid and Imaging Biomarker Changes in the MYHAT Study (University of Pittsburgh, USA
Thomas Karikari, PhDUniversity of Pittsburgh
11:20
The Correlation of plasma and Imaging Biomarkers with Clinical Performance in the AIBL and ADNeT Studies
Azadeh Feizpour, PhDFlorey Institute
11:40
Fluid and Imaging Biomarker Changes in the DIAN Study, Washington Univ. St Louis, USA
Brian Gordon, PhDWashington University in St Louis
12:00 pm
Keynote Fluid and Imaging Biomarkers for Diagnosis and Predicting Progression
Victor Villemagne, MDUniversity of Pittsburgh
12:30
Discussion/Q&A
1:00
Break

1:30

Session 2

Trials of Monoclonal Antibodies Directed Against Beta-Amyloid Protein

Co-Chairs: Eric McDade, DOWashington University in St Louis; Stephen Salloway, MD, MSButler Hospital

1:30
Session Overview
1:40
Clinical and Fluid and Imaging Biomarker Changes from the API ADAD Colombia Trial of Crenezumab
Pierre Tariot, MDBanner Alzheimer's Institute
2:00
Biomarker changes associated with Clinical Treatment Effects in the Trail Blazer Trials with Donanemab
Adam Fleisher, MD, MASEli Lilly & Co., Inc.
2:20
Biomarker changes associated with clinical treatment effects of Ganterenumab in the DIAN-TU-001 trial
Eric McDade, DOWashington University in St Louis
2:40
Keynote The Clarity AD Trial with Lecanemab and the Potential of Plasma Biomarkers for Tracking Treatment Response
Christopher van Dyck, MDYale University
3:10
Discussion/Q&A
3:40
END OF SYMPOSIUM

Workshop

Saturday, March 18, 2023

Full recording 149 min

10:00 ET
Welcome Notes
Ranjan Duara, MD, FAAN

10:05 ET

CSF and Blood Biomarkers for Lewy Body Disease (LBD)

Chair: James Galvin, MD, MPHUniversity of Miami and

10:05 am
Workshop Overview
10:15
Biology and Clinical Features of LBD and Distinction from AD and Other Neurodegenerative Diseases
James Galvin, MD, MPHUniversity of Miami
10:40
CSF Biomarker Findings in Lewy Body Dementia versus Alzheimer’s Disease
Lucilla Parnetti, MD, PhDUniversity of Perugia
11:05
Differential levels of Plasma Biomarkers of Neurodegeneration in Lewy Body Dementia, Alzheimer’s Disease, Frontotemporal Dementia and Progressive Supranuclear Palsy
Leonidas Chouliaras, MBBS, PhDCambridge University
11:30
Keynote a-Synuclein RT-QuIC and other Fluid Biomarkers for Assessment across the PD-DLB Spectrum
Douglas Galasko, MDUniversity of California, San Diego
12:10 pm
Discussion
12:40
END OF WORKSHOP

Public Forum

Sunday, April 2, 2023

Full recording 197 min

1:00pm ET
Introductory Notes
Ranjan Duara, MD, FAANMount Sinai Medical Center, Miami Beach, FL
Rosie Curiel Cid, PsyDUniversity of Miami Miller School of Medicine, Miami, FL
1:05
Introduction to Dementia, MCI, Alzheimer’s Disease, Amyloid, Tau and Neurodegeneration
Ranjan Duara, MD, FAANMount Sinai Medical Center, Miami Beach, FL
Rosie Curiel Cid, PsyDUniversity of Miami Miller School of Medicine, Miami, FL
1:30
Drugs likely to Receive Full FDA Approval in 2023/24: Efficacy, Adverse Effects, Mode of Delivery, Cost
Howard Feldman, MD, FRCP (C)University of California, San Diego, San Diego, CA
1:55
The Clarity Trial with Lecanemab for Alzheimer’s Disease
Christopher van Dyck, MDYale University School of Medicine
2:20
Non-Pharmacological Options for Treatment
Arlener Turner, PhDUniversity of Miami, Miami, FL
2:45
Treatment options, Ethical Issues and Decision Making
Jason Karlawish, MDPerelman School of Medicine, Philadelphia, PA
3:10
Summary Discussion
Moderator: David Knopman, MD
3:25
Concluding Remarks
Ranjan Duara, MD, FAANMount Sinai Medical Center, Miami Beach, FL
4:00
Forum Ends

Programs, recordings and slides as published at the time. Slides and recordings appear only where speakers chose to share them. Affiliations are as of 2023.